Update on World Health Organization HIV drug resistance prevention and assessment strategy: 2004-2011

M. R. Jordan; D. E. Bennett; M. A. Wainberg; D. Havlir; S. Hammer; C. Yang; L. Morris; M. Peeters; A. M. Wensing; N. Parkin; J. B. Nachega; A. Phillips; Andrea De Luca; E. Geng; A. Calmy; E. Raizes; P. Sandstrom; C. P. Archibald; J. Perriëns; C. M. Mcclure; S. Y. Hong; J. H. Mcmahon; N. Dedes; D. Sutherland; S. Bertagnolio

doi:10.1093/cid/cis206

Update on World Health Organization HIV drug resistance prevention and assessment strategy: 2004-2011

M. R. Jordan
, D. E. Bennett
, M. A. Wainberg
, D. Havlir
, S. Hammer
, C. Yang
, L. Morris
, M. Peeters
, A. M. Wensing
, N. Parkin
, J. B. Nachega
, A. Phillips
, Andrea De Luca
, E. Geng
, A. Calmy
, E. Raizes
, P. Sandstrom
, C. P. Archibald
, J. Perriëns
, C. M. Mcclure

S. Y. Hong, J. H. Mcmahon, N. Dedes, D. Sutherland, S. Bertagnolio

Università Cattolica del Sacro Cuore

World Health Organization
Centers for Disease Control and Prevention
McGill University
University of California at San Francisco
Columbia University
National Health Laboratory Services
Institut de recherche pour le développement
Utrecht University
Data First Consulting, Inc.
Stellenbosch University
University College London
Médecins Sans Frontière Access Campaign
Public Health Agency of Canada
Tufts University
International Treatment Preparedness Coalition

Risultato della ricerca: Contributo in rivista › Articolo

47 Citazioni (Scopus)

Abstract

The HIV drug resistance (HIVDR) prevention and assessment strategy, developed by the World Health Organization (WHO) in partnership with HIVResNet, includes monitoring of HIVDR early warning indicators, surveys to assess acquired and transmitted HIVDR, and development of an accredited HIVDR genotyping laboratory network to support survey implementation in resource-limited settings. As of June 2011, 52 countries had implemented at least 1 element of the strategy, and 27 laboratories had been accredited. As access to antiretrovirals expands under the WHO/Joint United Nations Programme on HIV/AIDS Treatment 2.0 initiative, it is essential to strengthen HIVDR surveillance efforts in the face of increasing concern about HIVDR emergence and transmission.

Lingua originale	Inglese
pagine (da-a)	S245-S245-9
Rivista	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Volume	54 Suppl 4
DOI	https://doi.org/10.1093/cid/cis206
Stato di pubblicazione	Pubblicato - 2012

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

SDG 3 Salute e benessere

Keywords

Anti-Retroviral Agents
Developing Countries
Drug Resistance, Viral
HIV Infections
Health Policy
Health Surveys
Humans
World Health
World Health Organization

Accesso al documento

10.1093/cid/cis206

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

Jordan, M. R., Bennett, D. E., Wainberg, M. A., Havlir, D., Hammer, S., Yang, C., Morris, L., Peeters, M., Wensing, A. M., Parkin, N., Nachega, J. B., Phillips, A., De Luca, A., Geng, E., Calmy, A., Raizes, E., Sandstrom, P., Archibald, C. P., Perriëns, J., ... Bertagnolio, S. (2012). Update on World Health Organization HIV drug resistance prevention and assessment strategy: 2004-2011. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 54 Suppl 4, S245-S245-9. https://doi.org/10.1093/cid/cis206

@article{9d824e68fd79492bb7ce6b1255e5ef50,

title = "Update on World Health Organization HIV drug resistance prevention and assessment strategy: 2004-2011",

abstract = "The HIV drug resistance (HIVDR) prevention and assessment strategy, developed by the World Health Organization (WHO) in partnership with HIVResNet, includes monitoring of HIVDR early warning indicators, surveys to assess acquired and transmitted HIVDR, and development of an accredited HIVDR genotyping laboratory network to support survey implementation in resource-limited settings. As of June 2011, 52 countries had implemented at least 1 element of the strategy, and 27 laboratories had been accredited. As access to antiretrovirals expands under the WHO/Joint United Nations Programme on HIV/AIDS Treatment 2.0 initiative, it is essential to strengthen HIVDR surveillance efforts in the face of increasing concern about HIVDR emergence and transmission.",

keywords = "Anti-Retroviral Agents, Developing Countries, Drug Resistance, Viral, HIV Infections, Health Policy, Health Surveys, Humans, World Health, World Health Organization, Anti-Retroviral Agents, Developing Countries, Drug Resistance, Viral, HIV Infections, Health Policy, Health Surveys, Humans, World Health, World Health Organization",

author = "Jordan, \{M. R.\} and Bennett, \{D. E.\} and Wainberg, \{M. A.\} and D. Havlir and S. Hammer and C. Yang and L. Morris and M. Peeters and Wensing, \{A. M.\} and N. Parkin and Nachega, \{J. B.\} and A. Phillips and \{De Luca\}, Andrea and E. Geng and A. Calmy and E. Raizes and P. Sandstrom and Archibald, \{C. P.\} and J. Perri{\"e}ns and Mcclure, \{C. M.\} and Hong, \{S. Y.\} and Mcmahon, \{J. H.\} and N. Dedes and D. Sutherland and S. Bertagnolio",

year = "2012",

doi = "10.1093/cid/cis206",

language = "English",

volume = "54 Suppl 4",

pages = "S245--S245--9",

journal = "Clinical infectious diseases : an official publication of the Infectious Diseases Society of America",

}

Jordan, MR, Bennett, DE, Wainberg, MA, Havlir, D, Hammer, S, Yang, C, Morris, L, Peeters, M, Wensing, AM, Parkin, N, Nachega, JB, Phillips, A, De Luca, A, Geng, E, Calmy, A, Raizes, E, Sandstrom, P, Archibald, CP, Perriëns, J, Mcclure, CM, Hong, SY, Mcmahon, JH, Dedes, N, Sutherland, D & Bertagnolio, S 2012, 'Update on World Health Organization HIV drug resistance prevention and assessment strategy: 2004-2011', Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, vol. 54 Suppl 4, pagg. S245-S245-9. https://doi.org/10.1093/cid/cis206

TY - JOUR

T1 - Update on World Health Organization HIV drug resistance prevention and assessment strategy: 2004-2011

AU - Jordan, M. R.

AU - Bennett, D. E.

AU - Wainberg, M. A.

AU - Havlir, D.

AU - Hammer, S.

AU - Yang, C.

AU - Morris, L.

AU - Peeters, M.

AU - Wensing, A. M.

AU - Parkin, N.

AU - Nachega, J. B.

AU - Phillips, A.

AU - De Luca, Andrea

AU - Geng, E.

AU - Calmy, A.

AU - Raizes, E.

AU - Sandstrom, P.

AU - Archibald, C. P.

AU - Perriëns, J.

AU - Mcclure, C. M.

AU - Hong, S. Y.

AU - Mcmahon, J. H.

AU - Dedes, N.

AU - Sutherland, D.

AU - Bertagnolio, S.

PY - 2012

Y1 - 2012

N2 - The HIV drug resistance (HIVDR) prevention and assessment strategy, developed by the World Health Organization (WHO) in partnership with HIVResNet, includes monitoring of HIVDR early warning indicators, surveys to assess acquired and transmitted HIVDR, and development of an accredited HIVDR genotyping laboratory network to support survey implementation in resource-limited settings. As of June 2011, 52 countries had implemented at least 1 element of the strategy, and 27 laboratories had been accredited. As access to antiretrovirals expands under the WHO/Joint United Nations Programme on HIV/AIDS Treatment 2.0 initiative, it is essential to strengthen HIVDR surveillance efforts in the face of increasing concern about HIVDR emergence and transmission.

AB - The HIV drug resistance (HIVDR) prevention and assessment strategy, developed by the World Health Organization (WHO) in partnership with HIVResNet, includes monitoring of HIVDR early warning indicators, surveys to assess acquired and transmitted HIVDR, and development of an accredited HIVDR genotyping laboratory network to support survey implementation in resource-limited settings. As of June 2011, 52 countries had implemented at least 1 element of the strategy, and 27 laboratories had been accredited. As access to antiretrovirals expands under the WHO/Joint United Nations Programme on HIV/AIDS Treatment 2.0 initiative, it is essential to strengthen HIVDR surveillance efforts in the face of increasing concern about HIVDR emergence and transmission.

KW - Anti-Retroviral Agents

KW - Developing Countries

KW - Drug Resistance, Viral

KW - HIV Infections

KW - Health Policy

KW - Health Surveys

KW - Humans

KW - World Health

KW - World Health Organization

KW - Anti-Retroviral Agents

KW - Developing Countries

KW - Drug Resistance, Viral

KW - HIV Infections

KW - Health Policy

KW - Health Surveys

KW - Humans

KW - World Health

KW - World Health Organization

UR - http://hdl.handle.net/10807/40454

U2 - 10.1093/cid/cis206

DO - 10.1093/cid/cis206

M3 - Article

VL - 54 Suppl 4

SP - S245-S245-9

JO - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

JF - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

ER -

Update on World Health Organization HIV drug resistance prevention and assessment strategy: 2004-2011

Abstract

OSS delle Nazioni Unite

Keywords

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo